Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Hemoglobinuria
About this trial
This is an observational trial for Paroxysmal Hemoglobinuria focused on measuring Hemolysis, CD55, CD59, Transfusion, Paroxysmal Nocturnal Hemoglobinuria, PNH
Eligibility Criteria
INCLUSION CRITERIA The following must be met before the subject may be enrolled: PNH patients with group A(1) blood who require at least three units of red cells as judged by their primary care physician; criteria for transfusion would include hemoglobin below 7.5 g/dl or symptoms related to anemia (impaired exercise tolerance, angina, shortness of breath) that warrant therapy. A PNH clone of greater than 40% and not have been transfused with group O blood for at least three months previously. Eighteen years of age or older. Karnofsky performance status of 60% or better. Adequate organ function as defined by serum creatinine less than 2.0 mg/dl. Able to comprehend and willing to sign an informed consent. EXCLUSION CRITERIA Any one of the following eliminates a subject from participating: Evidence of uncontrolled infection. Known alloimmunization to red cell antigens. Treatment with investigational agent or hematopoietic growth factors within 4 weeks of study entry. Psychiatric, addictive or any disorder that compromises ability to give truly informed consent. Patients who are moribund or who have concurrent hepatic, renal, cardiac disease.
Sites / Locations
- National Heart, Lung and Blood Institute (NHLBI)